Live
CellMitochondrial control of glycerolipid synthesis by a PEP shuttleCellFunctional RNA splitting drove the evolutionary emergence of type V CRISPR-Cas systems from transposonsCellDeep-learning-based <em>de novo</em> discovery and design of therapeutics that reverse disease-associated transcriptional phenotypesCellFour centuries of commercial whaling eroded 11,000 years of population stability in bowhead whalesFierceBiotechBeyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndromeEndpoints NewsLawmakers signal willingness to counter China’s biotech gainsEndpoints NewsSanofi, AbbVie, Novartis and AstraZeneca face revived 340B pricing caseEndpoints NewsFDA opens door to RMAT designations for therapies on clinical holdEndpoints NewsFDA seeks to encourage fewer animal studies with new draft guidanceBioPharma DiveRBC: Revolution, Xenon, Arrowhead among top takeover targetsBioPharma DiveJ&J wins FDA nod for psoriasis pill that aims to compete with top-selling injectionsFierceBiotechJenaValve's Trilogy valve secures FDA's 1st approval in aortic regurgitation
FierceBiotech Mar 18, 2026

Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome

Beyond seizures: With experimental drug, Stoke aims to restore developmental loss in Dravet syndrome

Original
Body unavailable. Use the original source.

Directory

59 All